Accreditation/Credit Designation

Medical Crossfire®: Practical Considerations for Integrations of Biosimilars Into Patient Care Pathways for Hematologic Malignancies, Rome, Italy, 27/09/2021-27/09/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participationinternational-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME Credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.

In order to help you issue individual certificates to each participant, please find below the breakdown of ECMEC®s per day: 28.09.2021 - 1.00

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.

ACCME Credits

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Pfizer Inc.

Medical Crossfire®: Practical Considerations for Integrations of Biosimilars Into Patient Care Pathways for Hematologic Malignancies

Release Date: November 1, 2021
Expiration Date: November 1, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in using biosimilars for the treatment of hematologic malignancies. In this educational program, these experts review regulatory considerations and best manufacturing practices for biosimilars, evaluate the efficacy and safety of biosimilars currently used for the management of hematologic malignancies, and discuss ways to navigate common barriers of biosimilar use with your patients.

This educational activity is an archive of the live virtual symposium held on September 27, 2021.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Pfizer Inc.
 

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is intended for hematologists, medical oncologists, and other health care professionals interested in the latest advances in the treatment of patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with hematologic malignancies are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Outline the manufacturing complexities and key processes in development of biosimilars
  • Identify key steps in the regulatory approval process for biosimilars
  • Assess barriers to application of biosimilars in clinical practice and the impact of real-world evidence to address these
  • Apply safety and efficacy data regarding biosimilars to the care of patients with hematologic malignancies

Faculty, Staff and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 

Chair

Naval G. Daver, MD
Naval G. Daver, MD
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas, USA

Disclosures: Grant/Research Support: AbbVie, Astellas, Bristol Myers Squibb, Daiichi-Sankyo, Forty Seven, Genentech, Gilead Sciences, ImmunoGen, Incyte, Kite Pharma, Novartis, Novimmune SA, Pfizer, Roche, Trillium Therapeutics; Consultant: AbbVie, Actinium Pharmaceuticals, Amgen, Astellas, Bristol Myers Squibb, Daiichi-Sankyo, Forty Seven, Genentech, Gilead Sciences, ImmunoGen, Incyte, Jazz, Novartis, Otsuka, Pfizer, Roche, Trillium Therapeutics.

Faculty

Claudio Cerchione, MD, PhD
Claudio Cerchione, MD, PhD
Director
Medical Research Hematology Unit
Romagnolo Scientific Institute for the Study and Treatment of Cancer
Meldola, Italy

Disclosures: Claudio Cerchione, MD, PhD, has no relevant financial relationships with ineligible companies.

Elias Jabbour, MD
Elias Jabbour, MD
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas, USA

Disclosures: Grant/Research Support: AbbVie Inc., Adaptive Biotechnologies; Amgen Inc., Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, Pfizer Inc., Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company.

Hagop M. Kantarjian, MD
Hagop M. Kantarjian, MD
Professor of Medicine
Chair, Department of Leukemia
Samsung Distinguished University Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas, USA

Disclosures: Grant/Research Support: AbbVie, Amgen, Ascentage Pharma, Bristol Myers Squibb, Daiichi-Sankyo, ImmunoGen, Jazz Pharmaceuticals, Pfizer, Sanofi.

Giovanni Martinelli, MD
Giovanni Martinelli, MD
Associate Professor
Department of Experimental, Diagnostic and Specialty Medicine
University of Bologna
Bologna, Italy

Scientific Director
Romagnolo Scientific Institute for the Study and Treatment of Cancer
Meldola, Italy

Disclosures: Grant/Research Support: Daiichi Sankyo, Incyte, Pfizer; Consultant: AbbVie, Pfizer, Roche; Speakers’ Bureau: Novartis.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By